Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year High – Should You Buy?

Vera Therapeutics, Inc. (NASDAQ:VERA) hit a new 52-week high on Thursday . The company traded as high as $56.05 and last traded at $55.26, with a volume of 481130 shares changing hands. The stock had previously closed at $53.91.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, October 8th. Bank of America boosted their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. TD Cowen lifted their target price on shares of Vera Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a research report on Friday, December 5th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Stock Up 2.5%

The firm has a market cap of $3.53 billion, a PE ratio of -13.85 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company’s 50-day simple moving average is $35.31 and its two-hundred day simple moving average is $27.82.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter in the previous year, the firm posted ($0.85) EPS. On average, analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the acquisition, the director owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the sale, the senior vice president owned 47,839 shares in the company, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in Vera Therapeutics in the 2nd quarter worth $51,000. Quarry LP increased its position in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after buying an additional 500 shares during the period. AlphaQuest LLC raised its stake in Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after buying an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after acquiring an additional 2,757 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.